Journal of Oncology Pharmacy Practice最新文献_第2页

Optimizing intermittent dosing of oral small molecule inhibitors.

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-03-21 DOI: 10.1177/10781552251327598

Jina Yun, Amy Ly Indorf

{"title":"Optimizing intermittent dosing of oral small molecule inhibitors.","authors":"Jina Yun, Amy Ly Indorf","doi":"10.1177/10781552251327598","DOIUrl":"https://doi.org/10.1177/10781552251327598","url":null,"abstract":"IntroductionWith recent expansion of oral small molecule inhibitors, the drug development studies need to provide insight into optimal dose selection for these agents with vastly different mechanism and pharmacokinetic considerations compared to our traditional chemotherapy agents. Currently there is one published meta-analysis that examines intermittent and alternative dosing of oral small molecule inhibitors and it is unclear what guidance is available for treatment personalization beyond package insert labeling for patients undergoing toxicities from treatment.MethodsA systematic review of oral small molecule inhibitors with intermittent dosing was conducted in the National Library of Medicine PubMed database. Studies were selected based on predefined inclusion/exclusion criteria. Data was extracted to summarize findings on available guidance for intermittent or alternative dosing of oral small molecule inhibitors. Studies were categorized based on food and drug administration (FDA) approved or non-FDA approved agents, and further characterized by comparison of different dosing schemas.ResultsFifty-five trials were included in the final review and data analysis. Thirty-three trials were phase 1 trials, 26 trials for FDA approved agents and 29 non-FDA approved agents. Most trials reported on agents used in solid tumors, particularly renal cell carcinoma, with most trials examining sunitinib. Of the 55 trials, 28 compared different dosing strategies with 26 of the 28 trials examining efficacy outcomes with 27 of the 28 trials examining safety outcomes.ConclusionsThis systematic review found limited guidance for clinicians in optimizing dosing for intermittently dosed oral small molecule inhibitors.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251327598"},"PeriodicalIF":1.0,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the impact of a pharmacist-led venetoclax ramp-up clinic for chronic lymphocytic leukemia patients: A retrospective chart review.

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-03-21 DOI: 10.1177/10781552251324522

Adrian de Boer, Chris McCaw, Margaret Ackman, Tara Leslie, Anthea Peters, Sheri Koshman

{"title":"Evaluating the impact of a pharmacist-led venetoclax ramp-up clinic for chronic lymphocytic leukemia patients: A retrospective chart review.","authors":"Adrian de Boer, Chris McCaw, Margaret Ackman, Tara Leslie, Anthea Peters, Sheri Koshman","doi":"10.1177/10781552251324522","DOIUrl":"https://doi.org/10.1177/10781552251324522","url":null,"abstract":"IntroductionVenetoclax is a BCL-2 inhibitor, used for both treatment-naive, and relapsed/refractory chronic lymphocytic leukemia (CLL). To mitigate the risk of tumor lysis syndrome (TLS), a 5-week dose ramp-up strategy with frequent assessment is required. Pharmacists are medication experts and skilled in managing adverse effects. They are ideally positioned to manage patients during ramp-up and can reduce hematologist visits. We sought to describe the impact of a pharmacist-led venetoclax ramp-up clinic implemented at our institution.MethodsThe primary objective was to describe pharmacist interventions made during ramp-up to prevent TLS. Key secondary objectives included describing the rates of TLS and rates of venetoclax target dose achievement. The study was a retrospective electronic chart review including CLL patients with ≥1 visit to the pharmacist-led clinic between October 2020-January 2024. Data was collected using a standardized form and descriptive statistics were used for analysis.ResultsEighty-eight patients were included. The median age was 70 years old and 97% of patients were low or moderate risk for TLS. Common interventions made for TLS prevention were education, occurring during all 907 patient visits, and changes to TLS prophylaxis, occurring during 113 (12.5%) patient visits. Two (2.3%) patients experienced laboratory TLS and 0 experienced clinical TLS. Eighty-three (94.3%) patients achieved target dose at the end of the study period.ConclusionsThe results of the study support that a pharmacist-led venetoclax clinic is both safe and effective for patients with CLL. Up-titration, active TLS prophylaxis, education and adverse event management are key components to the clinic.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251324522"},"PeriodicalIF":1.0,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between the profile of patients with chronic myeloid leukemia and adherence to tyrosine kinase inhibitors.

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-03-16 DOI: 10.1177/10781552251324845

Pryscila Rodrigues Moreira, Leonardo Teodoro de Farias, Tatyana Xavier Almeida Matteucci Ferreira, Raíza Guimarães Costa, Stanley Pontes Lacerda, Mariana Monteiro Palitot, Ana Carolina Figueiredo Modesto

{"title":"Association between the profile of patients with chronic myeloid leukemia and adherence to tyrosine kinase inhibitors.","authors":"Pryscila Rodrigues Moreira, Leonardo Teodoro de Farias, Tatyana Xavier Almeida Matteucci Ferreira, Raíza Guimarães Costa, Stanley Pontes Lacerda, Mariana Monteiro Palitot, Ana Carolina Figueiredo Modesto","doi":"10.1177/10781552251324845","DOIUrl":"https://doi.org/10.1177/10781552251324845","url":null,"abstract":"BackgroundTyrosine kinase inhibitors have substantially improved the quality of life and survival of patients with chronic myeloid leukemia. However, adherence is a complex and crucial aspect for achieving the desired clinical outcomes. Various factors can influence adherence, including the knowledge about the medications used in treatment.AimTo investigate the association between the clinical, sociodemographic and pharmacotherapeutic profile of patients with chronic myeloid leukemia and adherence to tyrosine kinase inhibitors.MethodThis is a cross-sectional study conducted in a specialized outpatient clinic for hematological diseases in the Central-West region of Brazil. Treatment adherence was assessed using the Morisky medication adherence scale and the medication possession ratio. A binary logistic regression was performed to investigate the extent to which adherence could be adequately predicted by the independent variables.ResultsThe study included 153 patients, with a mean age of 51.8 years and a predominance of males (59.5%). Low adherence was observed in 56.2% of patients (Morisky scale) and 24.8% (medication possession ratio). Among the predictors, being male increased the chances of low adherence by 2.22 times and having comorbidities by 2.17 times. Conversely, an increase in diagnosis time was associated with a 0,09 decrease in the chances of low adherence and \"Knowing what to do if you miss a dose\" was associated with a 0,58 lower chance of low adherence.ConclusionOur study emphasized that adherence can vary depending on the method used and that predictors related to clinical, sociodemographic and pharmacotherapeutic characteristics may be associated with low adherence.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251324845"},"PeriodicalIF":1.0,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143649368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating pharmacist preferences: Preparation of a novel on-body delivery system vs. high-resistance, manual syringes for large-volume subcutaneous drugs.

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-03-13 DOI: 10.1177/10781552251326574

Mehul Desai, Mitchell Blewett, Angela Yaniv, Adam Smith, Prit Patel, Catherine Loughran, Omar Rahman

{"title":"Evaluating pharmacist preferences: Preparation of a novel on-body delivery system vs. high-resistance, manual syringes for large-volume subcutaneous drugs.","authors":"Mehul Desai, Mitchell Blewett, Angela Yaniv, Adam Smith, Prit Patel, Catherine Loughran, Omar Rahman","doi":"10.1177/10781552251326574","DOIUrl":"https://doi.org/10.1177/10781552251326574","url":null,"abstract":"BackgroundAlthough syringe preparation for large-volume (>3 mL) subcutaneous (SC) drugs represents a significant workflow burden for pharmacists, their preferences for alternatives such as on-body delivery systems (OBDSs) are unexplored.ObjectiveTo evaluate pharmacists' preferences for preparing OBDSs vs. syringes.MethodsIn this cross-sectional study, pharmacists in US academic or community settings with experience preparing SC daratumumab/hyaluronidase (HYAL), rituximab/HYAL, pertuzumab/trastuzumab/HYAL, and/or efgartigimod/HYAL completed a double-blinded, 21-item, online survey that included questions about preferences regarding the preparation of prefilled syringes versus an OBDS.ResultsThirty pharmacists completed the survey. 100% responded that the OBDS appeared to be easy to prepare and easy to learn how to prepare and preferred it to syringe preparation. In response to a preparation scenario without reduced warming time that included preparation specifics, 86.67% preferred OBDS preparation to the syringe used to administer daratumumab/HYAL due to (1) time required to prepare the drug, (2) effort required to prepare the drug, and (3) optionality in drug preparation location. 29 pharmacists (96.67%) felt that the OBDS would reduce burden, 30 (100%) felt that it would improve efficiency, and 27 (90%) felt that it would reduce preparation errors. 22 pharmacists (73.33%) felt that the OBDS could provide optionality since it can be prepared outside of the pharmacy, and 100% felt that OBDS preparation would eliminate needlestick injuries.ConclusionPharmacists reported that an OBDS would be easy to prepare and to learn how to prepare and would improve pharmacy efficiency and safety compared with syringes used for large-volume SC drug administration.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251326574"},"PeriodicalIF":1.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gravimetric-based technology-assisted workflow system for injectable anticancer drugs compounding: Design and qualification of an original weighing scale anchored inside an isolator.

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-03-13 DOI: 10.1177/10781552251323868

Mélanie Brun, Julien Fouque, Hugo Palisson, Mallory Friou, Audrey Hurgon, Laurence Escalup, Laetitia Le, Alexandre Acramel

{"title":"Gravimetric-based technology-assisted workflow system for injectable anticancer drugs compounding: Design and qualification of an original weighing scale anchored inside an isolator.","authors":"Mélanie Brun, Julien Fouque, Hugo Palisson, Mallory Friou, Audrey Hurgon, Laurence Escalup, Laetitia Le, Alexandre Acramel","doi":"10.1177/10781552251323868","DOIUrl":"https://doi.org/10.1177/10781552251323868","url":null,"abstract":"Technology-assisted manufacturing such as computer-assisted gravimetric control (CAGC) is a well-established method for injectable anticancer drugs (AD) compounding. The aim of this study was to validate an innovative weighing scale (WS) anchored inside an isolator for in-process gravimetric control (GC) of injectable AD compounding in a French Comprehensive Cancer Centre. The weighing scale studied Cyto-TopControl® was designed by hospital pharmacists and the manufacturer LDI. Operational and performance qualification were carried out using weights ranging from 1 to 2000 g to assess fidelity, accuracy, linearity, eccentricity, precision and inter-test precision. The performance of the Cyto-TopControl® were compared to the standard WS model Cytocontrol® (LDI) by using a Bland-Altman plot. Infusion bags of four drugs (paclitaxel, docetaxel, epirubicin and trastuzumab) were then compounded by using CAGC associated with this new WS. For each preparation, an analytical control (AC) was carried out to validate the GC as a reference method. A total of 1530 weighings were performed. The maximum tolerated deviation and the accuracy deviations were not exceeded for each of the weights studied (<0.1 g for weights up to 100 g; <0.2 g for weight up to 2000 g). The standard deviations remained less than 5x 0.02 g and the linearity coefficients were above 0.9999. Eccentric weights coefficients of variation were less than 0.05%. The measurements obtained between Cyto-TopControl® and CytoControl® were consistent. Sixty bags were manufactured with the accuracy of 0.19% for GC and 5.07% for AC. This work confirms the reliability of this innovative WS for the in-process GC of injectable AD compounding.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251323868"},"PeriodicalIF":1.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of obesity on doxorubicin pharmacokinetics in women with breast cancer.

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-03-13 DOI: 10.1177/10781552251326045

Ronald G Hall, Shuhan Liu, Manjunath P Pai, William C Putnam, Indhumathy Subramaniyan, RajaReddy Kallem, Barbara Haley

{"title":"Impact of obesity on doxorubicin pharmacokinetics in women with breast cancer.","authors":"Ronald G Hall, Shuhan Liu, Manjunath P Pai, William C Putnam, Indhumathy Subramaniyan, RajaReddy Kallem, Barbara Haley","doi":"10.1177/10781552251326045","DOIUrl":"https://doi.org/10.1177/10781552251326045","url":null,"abstract":"IntroductionExperts suggest doxorubicin clearance is decreased in women with a body mass index (BMI) of ≥35 kg/m2. However, few data support this recommendation.MethodsWomen receiving doxorubicin for breast cancer in three BMI groups were recruited (n = 15). Doxorubicin dosing was determined by body surface area and was administered by 30-min intravenous infusion. Blood samples were obtained at 0 h (pre-dose) and 0.5, 1, 1.5, 2, 3, 4, 5, 12-24, and 24-72 h following the beginning of infusion. Concentrations of doxorubicin and its metabolite, doxorubicinol, were assayed by LC-MS/MS. Non-compartment analysis was done using PKanalix2021R2 for pharmacokinetic (PK) analyses.ResultsThe median [range] BMI and age were 30.3 [23.5-57] kg/m2 and 53 [31-69] years. Thirteen of the 15 women had samples available for analysis. Four of the 13 had a BMI ≥ 35.0 kg/m2. PK parameters ranged from 37.8% (AUC0-inf) to 91.0% (Vd). Doxorubicinol PK parameters ranged from 37.8% (Cmax) to 67.6% (AUC0-inf). The average doxorubicinol:doxorubicin AUClasts ratio was 0.26 (range: 0.04-0.88). A t-test didn't suggest a significant difference in individual PK parameters (BMI < 35 kg/m2 vs. ≥35.0 kg/m2). The two highest clearances (380 L/h and 250 L/h) had a BMI ≥ 35.0 kg/m2; also, the highest clearance (1114 L/h) for doxorubicinol was ≥35.0 kg/m2.ConclusionsLarge interindividual variabilities in doxorubicin PK were observed in women up to a BMI of 57 kg/m2 and a total body weight of 141.5 kg. Women with a BMI ≥ 35.0 kg/m2 and breast cancer did not appear to have lower clearances of doxorubicin.ClinicalTrials.gov IDNCT01537029.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251326045"},"PeriodicalIF":1.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Facts and figures of the compassionate use of onco-hematological drugs from 2016 to 2021: Results from the multicentric observational study Compass-O.

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-03-13 DOI: 10.1177/10781552251327117

Annamaria Mascolo, Irene Dell'Anno, Leonardo Dondi, Cristina Scavone, Annalisa Capuano, Marialuisa Giordano, Adriano Cristinziano, Domenico Tarantino, Marcello Pani, Carla Masini, Caterina Donati, Elisabetta Rossin, Graziella Lagana, Alice Ballerio, Gabriele Bagaglini, Gabriella Bonanni, Alberto Vergati, Arturo Cavaliere, Rosanna Celenza, Alessandro D'Arpino, Nello Martini, Carlo Piccinni

{"title":"Facts and figures of the compassionate use of onco-hematological drugs from 2016 to 2021: Results from the multicentric observational study Compass-O.","authors":"Annamaria Mascolo, Irene Dell'Anno, Leonardo Dondi, Cristina Scavone, Annalisa Capuano, Marialuisa Giordano, Adriano Cristinziano, Domenico Tarantino, Marcello Pani, Carla Masini, Caterina Donati, Elisabetta Rossin, Graziella Lagana, Alice Ballerio, Gabriele Bagaglini, Gabriella Bonanni, Alberto Vergati, Arturo Cavaliere, Rosanna Celenza, Alessandro D'Arpino, Nello Martini, Carlo Piccinni","doi":"10.1177/10781552251327117","DOIUrl":"https://doi.org/10.1177/10781552251327117","url":null,"abstract":"BackgroundCompassionate drug use (CDU) is a topic of debate in the scientific community characterized by a lack of information, especially in the onco-hematology area.AimThe Compass-O study aimed to provide updated data on CDU of onco-hematological drugs for the period 2016-2021.MethodCompass-O is a retrospective observational study with data obtained from 7 Italian Units for cytotoxic drug preparations (Unità Farmaci Antiblastici, UFA). Drugs and Therapeutic Indications (TI) were described separately and as drug-TI combinations, providing the mean Patients Per Year (mPPY) and the Years of Use (YoU).ResultsA total of 783 requests of CDU were retrieved, referring to 156.3 mPPY (max: 272 in 2021; min: 84 in 2018). The 52.2% of subjects was female, and the 63.2% aged >60 years. A total of 709 (90.5%) CDUs referred to solid tumors and 74 (9.5%) to liquid tumors. CDU referred to 93 drug-TI combinations. The most recurrent drug-TIs were nivolumab-lung carcinoma (mPPY: 36.5; YoU: 2) for solid tumors, and azacytidine-acute myeloid leukemia (6.0; 1) for liquid tumors. The most frequent TIs were lung carcinoma (45.7; 6) and breast cancer (37.0; 4) for solid tumors, and chronic lymphocytic leukemia (5.0; 2) and multiple myeloma (4.7; 6) for liquid tumors.ConclusionCompass-O provided an updated framework of the CDU in onco-hematology, showing its large-scale phenomenon and the relevance of UFA as a data source, underlining the need for a national observatory to monitor CDU.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251327117"},"PeriodicalIF":1.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mapping the patient journey: Understanding oral anticancer medication use among patients diagnosed with breast cancer.

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-03-13 DOI: 10.1177/10781552251323205

Yejin Seo, Karen Suchanek Hudmon, Kellie Jones Weddle, Yuehwern Yih, Kathy D Miller, Ephrem Abebe

{"title":"Mapping the patient journey: Understanding oral anticancer medication use among patients diagnosed with breast cancer.","authors":"Yejin Seo, Karen Suchanek Hudmon, Kellie Jones Weddle, Yuehwern Yih, Kathy D Miller, Ephrem Abebe","doi":"10.1177/10781552251323205","DOIUrl":"https://doi.org/10.1177/10781552251323205","url":null,"abstract":"IntroductionA growing number of patients with breast cancer use oral anticancer medications (OAMs) but may face barriers in managing their therapy at home, potentially impacting their treatment outcomes. Understanding these barriers is essential to designing effective interventions. This study aimed to identify unmet medication management needs of patients with breast cancer receiving OAMs.MethodsQualitative semi-structured interviews were conducted to create patient-specific journey maps describing OAM use. Participants were recruited from a federally qualified health center's breast cancer clinic in central Indiana. Eligible patients were 18 years of age or older, diagnosed with breast cancer, and currently receiving OAMs. Participants completed a sociodemographic survey, and researchers and participants collaborated to create visual storyboards of medication use experiences, highlighting timelines, key markers, and barriers. Journey maps were consolidated, and personas were created to represent patients with similar characteristics. Participants were categorized by medication type: specialty (requiring specialty pharmacies) or traditional (available at community pharmacies).ResultsTwelve participants (11 females, 1 male; median age 65.5 years, range 37-75) were interviewed. Four were receiving specialty medications (palbociclib, ribociclib), and eight were receiving traditional medications (tamoxifen, anastrozole, exemestane). Two personas were created. The specialty medication group reported difficulties navigating the insurance system, whereas the traditional group did not. All participants experienced side effects, and sub-optimal adherence (n = 2) was reported only in the traditional group.ConclusionThis study provides insights into the patient experience with OAMs. Personas and journey maps can guide the development of tailored interventions to improve treatment outcomes.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251323205"},"PeriodicalIF":1.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic outcomes of patients with acute erythroid leukemia treated with hypomethylating agents.

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-03-02 DOI: 10.1177/10781552251323578

Taylor Gabbard, Bernard L Marini, Kamran M Mirza, Lydia Benitez, Martina Fraga, Kristen M Pettit, Dale L Bixby, Patrick W Burke, Anthony J Perissinotti

{"title":"Therapeutic outcomes of patients with acute erythroid leukemia treated with hypomethylating agents.","authors":"Taylor Gabbard, Bernard L Marini, Kamran M Mirza, Lydia Benitez, Martina Fraga, Kristen M Pettit, Dale L Bixby, Patrick W Burke, Anthony J Perissinotti","doi":"10.1177/10781552251323578","DOIUrl":"https://doi.org/10.1177/10781552251323578","url":null,"abstract":"Acute erythroid leukemia treatment is associated with poor survival. The most common treatments are intensive chemotherapy regimens and hypomethylating agents. Choice of preferred therapy is complex, and data are conflicting on the optimal regimen. The definition of AEL has also shifted with time but the impacts of these changes on survival reporting are largely unknown.We designed a single-center, retrospective review of patients meeting the 2001 World Health Organization definition of acute erythroid leukemia. Patients were treated with an intensive chemotherapy or a hypomethylating agent regimen. The primary outcome was overall survival.Most patients were older with complex karyotypes. Median overall survival did not differ between treatment groups. When survival was stratified by WHO 2022 diagnosis, patients meeting MDS criteria had notably increased survival outcomes while patients still meeting the definition of AEL did poorly regardless of induction regimen.Treatment of acute erythroid leukemia remains complex with poor survival outcomes.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251323578"},"PeriodicalIF":1.0,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Qualitative analysis of clinical pharmacy interventions in an inpatient leukemia service. 对白血病住院服务中临床药学干预措施的定性分析。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-03-01 Epub Date: 2024-11-11 DOI: 10.1177/10781552241296407

Rand Al-Hadaddin, Nour Mustafa, Ahmad Alyamani, Nour Faqeer

{"title":"Qualitative analysis of clinical pharmacy interventions in an inpatient leukemia service.","authors":"Rand Al-Hadaddin, Nour Mustafa, Ahmad Alyamani, Nour Faqeer","doi":"10.1177/10781552241296407","DOIUrl":"10.1177/10781552241296407","url":null,"abstract":"IntroductionLeukemia, a complex hematological malignancy, requires a multidisciplinary treatment approach, with clinical pharmacists playing a crucial role. However, their involvement in clinical practice is not well-documented in the literature. This study aimed to examine the characteristics of clinical pharmacy interventions (CPIs) reported by clinical pharmacists.MethodThis retrospective study involved extraction of CPIs entered into a pharmacy documentation database \"Quantifi®\" between January 2019 and June 2023. These CPIs included direct clinical pharmacist interventions (DCPIs), detected medication errors (MEs) and adverse drug reactions (ADRs).ResultsA total of 6286 CPIs were extracted, of which DCPIs, MEs and ADRs accounted for 5701 (90.7%), 357 (5.7%) and 228 (3.6%) reports, respectively. The most prevalent DCPIs were drug therapy discontinuation (n = 1080, 18.9%). Antimicrobials were the most common medications associated with DCPIs (n = 1991, 34.9%). Physicians accepted 99.4% of DCPIs and 64.1% (n = 3656) of direct interventions were considered significant. Among detected MEs, antimicrobials were the most reported medications (n = 158, 44.3%), with pharmacy internal errors being the most prevalent cause of the events (n = 172, 48.2%). Among the reported ADRs, hematological reactions were the most common (n = 81, 35.5%), and antineoplastic agents were the most frequently associated medications with ADRs (n = 164, 71.9%).ConclusionThis study highlights the crucial role of clinical pharmacists in managing leukemia patients, emphasizing their key interventions and ability to identify MEs and ADRs. Further research is needed to explore the clinical outcomes and financial impact of their involvement.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"276-281"},"PeriodicalIF":1.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0